China's Stemirna to raise $50m for clinical trials of COVID vaccine pipeline

Stemirna Therapeutics, a Chinese biotech startup specialized in RNA technology-based drug development, has entered into a staged investment agreement with Shanghai-listed domestic pharma Tibet Rhodiola Pharmaceutical that could bring the startup capital injections of up to 351 million yuan ($50 million).